Roche Believes Biomarker Could Position Antibody For Severe Asthma For Success
This article was originally published in The Pink Sheet Daily
Executive Summary
During an investor presentation Nov. 7, the Swiss pharma outlined its plans to move lebrikizumab into Phase III next year.
You may also be interested in...
Genentech Seeks Partners For Biomarker-Driven Drug Development Beyond Oncology
Roche subsidiary hopes recent deals with 23andMe and Human Longevity for whole genome sequencing will help identify targets and biomarkers for Parkinson's disease and other non-cancer conditions. Firm also is taking a personalized medicine approach to development of treatments for pain, macular degeneration and asthma.
On The Respiratory Horizon: A Wave Of Biologics For Asthma
Several antibody drugs are in late-stage development to treat severe asthma and could reach the market in the next two years. But competition for niche subsets of patients will be fierce, and tailoring the right medications to the right patients to justify the higher cost of treatment will require advances in biomarker development.
Roche Third-Quarter Pipeline Adjustments Include Advancements, Delays
Roche adjusted regulatory expectations for its pipeline during a third-quarter earnings call Oct. 16, moving up filing plans for onartuzumab (MetMAb) in metastatic non-small cell lung cancer to 2014 and pushing back an ocrelizumab filing in multiple sclerosis to 2015, both based on trial enrollment rates.